BACKGROUND & AIMS: Prograstrin induces proliferation in colon crypts by activating p65nuclear factor-κB (NF-κB) (p65) and β-catenin. We investigated whether Annexin A2 (AnxA2), a progastrin receptor, activates NF-κB and β-catenin in vivo. METHODS: ANXA2-null (ANXA2(-/-)) and wild-type (ANXA2(+/+)) mice were studied, along with clones of progastrin-responsive HEK-293 cells that stably expressed full-length progastrin (HEK-mGAS) or an empty vector (HEK-C). Small interfering RNA was used to down-regulate AnxA2, p65NF-κB, and β-catenin in cells. RESULTS: Proliferation and activation of p65 and β-catenin increased significantly in HEK-mGAS compared with HEK-C clones. HEK-mGAS cells had a 2- to 4-fold increase in relative levels of c-Myc, cyclooxygenase (COX)-2, CyclinD1, double cortin CAM kinase-like 1 (DCAMKL+1), and CD44, compared with HEK-C clones. Down-regulation of AnxA2 in HEK-mGAS clones reduced activation of NF-κB and β-catenin, as well as levels of DCAMKL+1. Surprisingly, down-regulation of β-catenin had no effect on activation of p65NF-κB, whereas down-regulation of p65 significantly reduced activation of β-catenin in HEK-mGAS clones. Loss of either p65 or β-catenin significantly reduced proliferation of HEK-mGAS clones, indicating that both factors are required for the proliferative effects of progastrin. Lengths of colon crypts and levels of p65, β-catenin, DCAMKL+1, and CD44 were significantly higher in ANXA2(+/+) mice compared with either ANXA2(-/-) mice given progastrin or ANXA2(+/+) and ANXA2(-/-) mice given saline. CONCLUSIONS: AnxA2 expression is required for the biologic effects of progastrin in vivo and in vitro and mediates the stimulatory effect of progastrin on p65NF-κ, β-catenin, and the putative stem cell markers DCAMKL+1 and CD44. AnxA2 might therefore mediate the hyperproliferative and cocarcinogenic effects of progastrin.
BACKGROUND & AIMS: Prograstrin induces proliferation in colon crypts by activating p65nuclear factor-κB (NF-κB) (p65) and β-catenin. We investigated whether Annexin A2 (AnxA2), a progastrin receptor, activates NF-κB and β-catenin in vivo. METHODS:ANXA2-null (ANXA2(-/-)) and wild-type (ANXA2(+/+)) mice were studied, along with clones of progastrin-responsive HEK-293 cells that stably expressed full-length progastrin (HEK-mGAS) or an empty vector (HEK-C). Small interfering RNA was used to down-regulate AnxA2, p65NF-κB, and β-catenin in cells. RESULTS: Proliferation and activation of p65 and β-catenin increased significantly in HEK-mGAS compared with HEK-C clones. HEK-mGAS cells had a 2- to 4-fold increase in relative levels of c-Myc, cyclooxygenase (COX)-2, CyclinD1, double cortin CAM kinase-like 1 (DCAMKL+1), and CD44, compared with HEK-C clones. Down-regulation of AnxA2 in HEK-mGAS clones reduced activation of NF-κB and β-catenin, as well as levels of DCAMKL+1. Surprisingly, down-regulation of β-catenin had no effect on activation of p65NF-κB, whereas down-regulation of p65 significantly reduced activation of β-catenin in HEK-mGAS clones. Loss of either p65 or β-catenin significantly reduced proliferation of HEK-mGAS clones, indicating that both factors are required for the proliferative effects of progastrin. Lengths of colon crypts and levels of p65, β-catenin, DCAMKL+1, and CD44 were significantly higher in ANXA2(+/+) mice compared with either ANXA2(-/-) mice given progastrin or ANXA2(+/+) and ANXA2(-/-) mice given saline. CONCLUSIONS:AnxA2 expression is required for the biologic effects of progastrin in vivo and in vitro and mediates the stimulatory effect of progastrin on p65NF-κ, β-catenin, and the putative stem cell markers DCAMKL+1 and CD44. AnxA2 might therefore mediate the hyperproliferative and cocarcinogenic effects of progastrin.
Authors: Yuhang Zhang; Philip Tomann; Thomas Andl; Natalie M Gallant; Joerg Huelsken; Boris Jerchow; Walter Birchmeier; Ralf Paus; Stefano Piccolo; Marja L Mikkola; Edward E Morrisey; Paul A Overbeek; Claus Scheidereit; Sarah E Millar; Ruth Schmidt-Ullrich Journal: Dev Cell Date: 2009-07 Impact factor: 12.270
Authors: Guangchun Jin; Vigneshwaran Ramanathan; Michael Quante; Gwang Ho Baik; Xiangdong Yang; Sophie S W Wang; Shuiping Tu; Shanisha A K Gordon; David Mark Pritchard; Andrea Varro; Arthur Shulkes; Timothy C Wang Journal: J Clin Invest Date: 2009-08-03 Impact factor: 14.808
Authors: Yusuke Shiozawa; Aaron M Havens; Younghun Jung; Anne M Ziegler; Elisabeth A Pedersen; Jingcheng Wang; Jianhua Wang; Ganwei Lu; G David Roodman; Robert D Loberg; Kenneth J Pienta; Russell S Taichman Journal: J Cell Biochem Date: 2008-10-01 Impact factor: 4.429
Authors: Kristin K Fino; Gail L Matters; Christopher O McGovern; Evan L Gilius; Jill P Smith Journal: Am J Physiol Gastrointest Liver Physiol Date: 2012-03-22 Impact factor: 4.052
Authors: Carrie A Duckworth; Daniel Clyde; Daniel L Worthley; Timothy C Wang; Andrea Varro; D Mark Pritchard Journal: Gastroenterology Date: 2013-03-19 Impact factor: 22.682
Authors: Shubhashish Sarkar; Malaney R O'Connell; Yoshinaga Okugawa; Brian S Lee; Yuji Toiyama; Masato Kusunoki; Robert D Daboval; Ajay Goel; Pomila Singh Journal: Mol Cancer Res Date: 2017-08-29 Impact factor: 5.852